Does HPV-status play a role in selection of immune checkpoint inhibitors in upfront treatment of metastatic head and neck cancer?

In my practice, HPV-status in isolation does not play a role in selection of immune checkpoint inhibitors in initial treatment of recurrent/metastatic head/neck squamous cell cancer (R/M HNSCC).

The current FDA approval for first-line management of R/M HNSCC is for pembrolizumab in combination with ...

I agree with Dr. @Dr. First Last. To add one point, the only HPV positive patients who demonstrate a more favorable response to those who tumors have high mutational burdens. Otherwise, in my practice, as his, I base treatment checkpoint inhibitors on PDL-1 expression, e.g. CPS.